A STUDY OF THE BENEFICIAL EFFECTS OF ANTICOAGULANT THERAPY IN CONGESTIVE HEART FAILURE
Authors: G C GRIFFITH, R STRAGNELL, D C LEVINSON, F J MOORE, A G WARE
Journal: Annals of Internal Medicine (1952)

Article1 November 1952A STUDY OF THE BENEFICIAL EFFECTS OF ANTICOAGULANT THERAPY IN CONGESTIVE HEART FAILUREGEORGE C. GRIFFITH, M.D., F.A.C.P., ROBERT STRAGNELL, M.D., DAVID C. LEVINSON, M.D., FREDERICK J. MOORE, M.D., ARNOLD G. WARE, Ph. D.GEORGE C. GRIFFITH, M.D., F.A.C.P., ROBERT STRAGNELL, M.D., DAVID C. LEVINSON, M.D., FREDERICK J. MOORE, M.D., ARNOLD G. WARE, Ph. D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-37-5-867 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThromboemboli are a frequent cause of death in patients with congestive heart failure. In 565 patients with rheumatic heart disease and congestive heart failure, autopsied at the Los Angeles County Hospital,1thromboemboli were found in 30.3 per cent. In 114 patients thromboemboli were the direct cause of death, in 20 patients a contributory cause of death, and in 28 patients did not contribute to death. Despite this fact, anticoagulants have not been widely used as an adjuvant to routine therapy. Several groups2a, b, 3, 4have studied this problem and report a 5.8 to 8 per cent reduction in mortality,...Bibliography1. Erman M: Unpublished observations. Google Scholar2a. AndersonHull GME: The use of Dicumarol as an adjunct to the treatment of congestive heart failure. Results in a controlled series of 61 cases, South. M. J. 41: 365, 1948. CrossrefMedlineGoogle Scholar2b. AndersonHull GME: The effect of Dicumarol upon the mortality and the incidence of thromboemboli in congestive heart failure, Am. Heart J. 39: 697, 1950. CrossrefMedlineGoogle Scholar3. WishartChapman JHCB: Dicumarol therapy in congestive heart failure, New England J. Med. 239: 701, 1948. CrossrefMedlineGoogle Scholar4. HarveyFinch WPCA: Dicumarol prophylaxis of thromboembolic disease in congestive heart failure, New England J. Med. 242: 208, 1950. CrossrefMedlineGoogle Scholar5. LevinsonGriffith DCGC: Evaluation of anticoagulant therapy in congestive heart failure, Circulation 4: 416, 1951. CrossrefMedlineGoogle Scholar6. LeeWhite RIPD: A clinical study of the coagulation of blood, Am. J. M. Sc. 145: 495, 1913. CrossrefGoogle Scholar7. Quick AJ: The hemorrhagic diseases and the physiology of hemostasis, 1942, C. C. Thomas, Springfield, Ill., p. 312. Google Scholar8. WareStragnell AGR: An improved one-stage prothrombin method, Am. J. Clin. Path. 22: 791, 1952. CrossrefMedlineGoogle Scholar9. Owren PA: A quantitative one-stage method for assay of prothrombin, Scand. J. Clin. and Lab. Invest. 1: 81, 1949. CrossrefMedlineGoogle Scholar10. MooreCramerKnowles FJFBRG: Statistics for medical students, 1951, The Blakiston Company, Philadelphia. Google Scholar11. BrambelHunterFitzpatrick CEREVd: Prophylactic use of anticoagulants in the puerperal period (Dicumarol, Heparin and Link Compound 63), Bull. School Med. Univ. Maryland 35: 91, 1950. MedlineGoogle Scholar12. MarpleWright CDIS: Thromboembolic conditions and their treatment with anticoagulants, 1950, C. C. Thomas, Springfield, Ill., p. 95. Google Scholar13. Nichol RS: Risk of hemorrhage in anticoagulant therapy, Ann. West. Med. and Surg. 4: 71, 1950. MedlineGoogle Scholar14. WrightRothman LTM: Deaths from Dicumarol, Arch. Surg. 63: 23, 1951. CrossrefGoogle Scholar15. LeedhamOrbison CLJA: Cardiac tamponade associated with the administration of Dicumarol, Circulation 1: 1065, 1950. CrossrefGoogle Scholar16. WatkinVan ItallieLoganGeyerDavidsonStare DMTBWBRPCSFW: The treatment of Dicumarol-induced hypo-prothrombinemia in man with emulsified vitamin K1 administered intravenously, J. Lab. and Clin. Med. 37: 269, 1951. MedlineGoogle Scholar17. OwrenAas PK: The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin, Scand. J. Clin. and Lab. Invest. 3: 201, 1951. CrossrefMedlineGoogle Scholar18. AstrupMüllertzHansen TSJR: The value of Owren's method of estimating prothrombin, Scand. J. Clin, and Lab. Invest. 3: 209, 1951. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Los Angeles, California*Presented at the Thirty-third Annual Session of the American College of Physicians, Cleveland, Ohio, April 23, 1952.From the Department of Medicine (Cardiology), the Department of Medicine (Experimental), and the Department of Biochemistry and Nutrition, University of Southern California School of Medicine and the Los Angeles County Hospital.Aided by grants from the Upjohn Company, Geigy Pharmaceuticals and the Los Angeles Heart Association.†Trainee of the National Heart Institute 1950-51.‡Trainee of the National Heart Institute 1949-50.§Tromexan kindly furnished by Geigy Pharmaceuticals, 220 Church St., New York City.**Depo-Heparin kindly furnished by the Upjohn Co., Kalamazoo, Michigan. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySchlaganfall-Prophylaxe bei Herzinsuffizienz und DissektionAnticoagulation versus placebo for heart failure in sinus rhythmEfficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort StudiesThe Role of Antithrombotic Therapy in Heart FailureNet clinical benefit of antithrombotic therapy in patients with heart failure and sinus rhythm: A network meta-analysis from 5 clinical trialsSecondary Prevention After Cardioembolic StrokeAnticoagulation in Patients With Left Ventricular Systolic Dysfunction and Sinus RhythmAnticoagulation versus placebo for heart failure in sinus rhythmAntiplatelet and Anticoagulant Agents in Heart FailureAntithrombotics in Heart Failure With Reduced Ejection Fraction and Normal Sinus Rhythm2013 ACCF/AHA Guideline for the Management of Heart Failure2013 ACCF/AHA Guideline for the Management of Heart FailureAnticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing BoardClinical Effectiveness of Anticoagulation Therapy Among Older Patients With Heart Failure and Without Atrial Fibrillation: Findings From the ADHERE Registry Linked to Medicare ClaimsOral Anticoagulation Therapy in Heart Failure Patients in Sinus Rhythm: A Systematic Review and Meta-AnalysisPrevalence of left chamber cardiac thrombi in patients with dilated left ventricle at sinus rhythm: The role of transesophageal echocardiographyAnticoagulation Therapy in Patients With Heart Failure Due to Systolic Dysfunction and Sinus Rhythm: Analysis of REDINSCOR RegistryTratamiento anticoagulante en pacientes con insuficiencia cardiaca por disfunción sistólica y ritmo sinusal: análisis del registro REDINSCORThrombo‐embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on ThrombosisAnticoagulation versus placebo for heart failure in sinus rhythmB-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the Acute Decompensated Heart Failure National RegistryWarfarin and Aspirin in Patients with Heart Failure and Sinus RhythmWhen Oral Anticoagulation Therapy is Needed in Patients With Cardiomyopathies: A Review of LiteratureThromboembolism and antithrombotic therapy for heart failure in sinus rhythmPrevention of Cardioembolic StrokeThe Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society GuidelinesThe Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive SummarySecondary Prevention of Cardioembolic StrokeOral Anticoagulation With Warfarin for Patients With Left Ventricular Systolic DysfunctionDilated Cardiomyopathy and Role of Antithrombotic TherapyRandomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) TrialAntithrombotic therapy for heart failure in sinus rhythmAnticoagulation for heart failure: selecting the best therapyRandomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart FailureAntithrombotic Therapy in Heart FailureAnticoagulation in patients with heart failure and normal sinus rhythmStroke Prevention in Atrial Fibrillation and Other Major Cardiac Sources of EmbolismThe Role for Anticoagulation with Warfarin in Patients with Systolic Heart Failure and Normal Sinus RhythmThe Primary and Secondary Prevention of Coronary Artery DiseaseThromboembolic risk in the patient with heart failureAntithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implicationsAnticoagulation in patients with heart failure: who, when, and why?Warfarin Versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): Rationale, Objectives, and DesignAntithrombotic therapy for congestive heart failureAntithrombotic Therapy for Coronary Artery DiseaseThe Warfarin/Aspirin study in heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failureThe Warfarin and Antiplatelet Therapy in Heart Failure Trial (WATCH): rationale, design, and baseline patient characteristicsBlood Coagulation in Patients with Chronic Heart FailureEffects of acute exercise on hemorheological, endothelial, and platelet markers in patients with chronic heart failure in sinus rhythmAbnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus RhythmAnticoagulation for heart failure in sinus rhythmAntiplatelet and anticoagulant therapy inthe prevention of thromboemboli in chronic heart failureIntracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.Cardioversion of atrial fibrillation.Cardioversion of atrial fibrillationAntithrombotic Therapy in Atrial FibrillationAntithrombotic Therapy in Atrial FibrillationAntithrombotic Therapy in Atrial FibrillationCurrent status of antithrombotic therapy in cardiovascular diseasePrevention of venous thromboembolismTreatment of the Patient With Refractory Heart FailurePharmacological Considerations of Antithrombotic TherapyTherapie der HerzinsuffizienzDie Coronarerkrankungen. Coronarinsuffizienz, Angina pectoris und HerzinfarktANTICOAGULANT THERAPY: ELIMINATION OF SOME COMMONLY OCCURRING PITFALLS*ARNOLD G. WARE, PH.D., ROBERT STRAGNELL, M.D.The present status of anticoagulantsTHE CONTROL OF EXCESSIVE EFFECT BY ANTICOAGULANTS*†IVAN F. DUFF, M.D., JOHN R. GAMBLE, M.D., PARK W. WILLIS III, M.D., PAUL E. HODGSON, M.D., WILLIAM S. WILSON, M.D., JOSIAH A. POLHEMUS, M.D.ANTICOAGULANTS IN CARDIOVASCULAR DISEASEDoes Rapid Dehydration in Cardiac Decompensation Produce Thromboembolic Complications? 1 November 1952Volume 37, Issue 5Page: 867-887KeywordsAnticoagulant therapyAnticoagulantsBiochemistryCardiovascular therapyHeartHeart failureHospital medicineLongitudinal studiesMortalityNutrition ePublished: 1 December 2008 Issue Published: 1 November 1952 PDF downloadLoading ...